Ranibizumab Prefilled Syringes: Benefits of Reduced Syringe Preparation Times and Less Complex Preparation Procedures
Authors:
- 18 May 2015
- journal article
- research article
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 25 (6) , 529-534
Abstract
Purpose: A recently developed ranibizumab prefilled syringe (PFS) eliminates several preparatory steps versus the standard vial-based method, and is expected to reduce syringe preparation time (SPT) and enhance procedural simplicity for intravitreal injections. Methods: Syringe preparation times for the ranibizumab PFS and vial were recorded during standard treatment sessions at 2 centers, without randomization. The duration of each step in preparing the syringe was recorded. At each center, total SPT (mean total duration of all syringe preparation steps) for each method was compared using a 2-tailed t test. Results: In total, 97 SPTs were analyzed across both centers. Center 1 SPTs were 46 seconds (PFS) versus 75 seconds (vial; difference, 29 seconds; p<0.001). Center 2 SPTs were 46 seconds (PFS) versus 63 seconds (vial; difference, 17 seconds; p<0.001). This equates to a 27%-39% reduction in SPT when using the PFS rather than the vial, resulting mostly from the reduced number of syringe preparation steps associated with the PFS. Conclusions: Syringe preparation times for ranibizumab intravitreal injections are significantly shorter with the PFS than with the vial. The time saved by using the PFS may benefit physicians and nurses, and the simplicity of the injection preparation process with the PFS is advantageous.Keywords
This publication has 14 references indexed in Scilit:
- RADIANCE: A Randomized Controlled Study of Ranibizumab in Patients with Choroidal Neovascularization Secondary to Pathologic MyopiaOphthalmology, 2014
- Angepasstes und standardisiertes Patientenmanagement bei der Behandlung der neovaskulären AMD im ambulanten Bereich einer Universitäts-AugenklinikKlinische Monatsblätter für Augenheilkunde, 2012
- The RESTORE StudyOphthalmology, 2011
- New paradigms in the treatment of wet AMD: the impact of anti-VEGF therapyEye, 2009
- Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR StudyOphthalmology, 2009
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Leading causes of certification for blindness and partial sight in England & WalesBMC Public Health, 2006
- Causes and Prevalence of Visual Impairment Among Adults in the UnitedStatesArchives of Ophthalmology (1950), 2004
- How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?British Journal of Ophthalmology, 2003
- Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal DisordersNew England Journal of Medicine, 1994